Trial Profile
A Phase I Biological Study of Intraveous Azacitidine (Vidaza) in Hematologic Malignancies
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 25 Sep 2009
Price :
$35
*
At a glance
- Drugs Azacitidine (Primary)
- Indications Acute myeloid leukaemia; Chronic lymphocytic leukaemia; Chronic myeloid leukaemia; Hodgkin's disease; Multiple myeloma; Myelodysplastic syndromes; Myeloproliferative disorders; Non-Hodgkin's lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions
- 11 Sep 2009 Additional lead trial investigator (O'Connell C) added as reported by University of Southern California Norris Comprehensive Cancer Center record.
- 15 Oct 2007 New trial record.